Cited by 41Antifungal resistance and susceptibilityFungal and yeast genetics researchFungal Infections and Studies

The Rim pathway mediates antifungal tolerance in Candida albicans through newly identified Rim101 transcriptional targets, including Hsp90 and Ipt1

Open access
Garnaud, Cécile, García-Oliver, Encar, Wang, Yan, Maubon, Danièle, Bailly, Sébastien, Despinasse, Quentin, Champleboux, Morgane, Govin, Jérôme +1 more·2018·Antimicrobial Agents and Chemotherapy

Abstract

ABSTRACT Invasive candidiasis (IC) is a major cause of morbidity and mortality despite antifungal treatment. Azoles and echinocandins are used as first-line therapies for IC. However, their efficacy is limited by yeast tolerance and the emergence of acquired resistance. Tolerance is a reversible stage created due to the yeast's capacity to counter antifungal drug exposure, leading to persistent growth. For Candida albicans , multiple stress signaling pathways have been shown to contribute to this adaptation. Among them, the pH-responsive Rim pathway, through its transcription factor Rim101p, was shown to mediate azole and echinocandin tolerance. The Rim pathway is fungus specific, is conserved among the members of the fungal kingdom, and plays a key role in pathogenesis and virulence. The present study aimed at confirming the role of Rim101p and investigating the implication of the other Rim proteins in antifungal tolerance in C. albicans , as well as the mechanisms underlying it. Time-kill curve experiments and colony formation tests showed that genetic inhibition of all the Rim factors enhances echinocandin and azole antifungal activity. Through RNA sequencing analysis of a rim101 −/− mutant, a strain constitutively overexpressing RIM101 , and control strains, we discovered novel Rim-dependent genes involved in tolerance, including HSP90 , encoding a major molecular chaperone, and IPT1 , involved in sphingolipid biosynthesis. Rim mutants were also hypersensitive to pharmacological inhibition of Hsp90. Taken together, these data suggest that Rim101 acts upstream of Hsp90 and that targeting the Rim pathway in combination with existing antifungal drugs may represent a promising antifungal strategy to indirectly but specifically target Hsp90 in yeasts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01785-17

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Garnaud, C., García-Oliver, E., Wang, Y., Maubon, D., Bailly, S., Despinasse, Q., Champleboux, M., Govin, J., & Cornet, M.
Affiliations
  • Institut polytechnique de Grenoble (FR)
  • Inserm (FR)
Venue
Antimicrobial Agents and Chemotherapy
Published
2018-03
Volume
62
Issue
3
Pages
e01785-17
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2783406767
Cited by
41
References
53
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 3 · 2021: 6 · 2020: 9 · 2019: 1 · 2018: 1
FWCI
3.21
Type
journal article
Language
en
Open access
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Agence Nationale de la Recherche (ANR-11-PDOC-0011)
  • Fondation pour la Recherche Médicale (SPF20140129159)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
Rim101, Candida albicans, antifungal tolerance, invasive candidiasis, HSP90, sphingolipid biosynthesis, azole resistance, echinocandin resistance, transcription factor target genes
MeSH terms
Antifungal Agents, Azoles, Candida albicans, Fungal Proteins, Signal Transduction, HSP90 Heat-Shock Proteins, Echinocandins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review